What Is PTSD? Symptoms, Causes, and Evidence-Based Treatment Options

PTSD is not a reaction to being too sensitive or too weak. It is a physiological consequence of how the brain processes certain types of severe threat. The memory systems involved in traumatic experiences work differently from everyday memory, and when that process goes wrong, the result is a condition that does not resolve the way a normal bad memory does.

Understanding what PTSD is, who develops it, and why the treatment approach matters as much as the treatment itself, is the foundation of navigating recovery.

What This Page Covers

• What PTSD is and how it develops
• Who is at risk and why some people develop PTSD after trauma while others do not
• The four symptom clusters and what they look like
• How PTSD is diagnosed
• First-line treatment: what the 2025 APA guidelines recommend
• Medications approved for PTSD and their role
• Why benzodiazepines are explicitly not recommended
• What ongoing care and support look like

What PTSD Is

Post-traumatic stress disorder (PTSD) is a psychiatric condition that can develop after a person is exposed to a traumatic event or series of events. PTSD may be diagnosed when symptoms last for an extended period after a traumatic event and begin to interfere with aspects of daily life, such as relationships or work.

PTSD is not limited to combat veterans, though that association persists in popular understanding. Assault, serious accidents, natural disasters, childhood abuse, medical trauma, and witnessing violence can all produce PTSD in civilian populations. PTSD affects approximately 5% of U.S. adults in any given year, and nearly 6 in 100 people will be diagnosed with PTSD in their lifetime. Women are approximately twice as likely as men to develop PTSD following trauma exposure.

What distinguishes PTSD from a normal stress reaction is persistence and impairment. Most people have acute distress after trauma. PTSD is when that distress does not resolve, when the brain continues to process the event as an ongoing threat rather than a past one.

How PTSD Develops: The Neuroscience

Traumatic memory is encoded differently than ordinary memory. In high-threat situations, the amygdala (the brain’s threat-detection center) takes over memory consolidation from the hippocampus, which normally organizes memories with a clear time stamp, context, and narrative arc. The result is a fragmented, sensory-driven memory that lacks the contextual markers that signal “this is in the past.”

When something triggers that memory, the brain does not retrieve a past event. It reactivates it, producing the full physiological fear response as if the threat were current. Flashbacks are not just vivid memories. They are partial re-activations of the original threat state.

Multiple neurobiological pathways are implicated in PTSD, including dysregulation of monoaminergic neurotransmitters, abnormalities in cortical-limbic networks, and alterations in the hypothalamic-pituitary-adrenal axis. These changes are measurable, not imagined.

This neurobiological foundation explains both why PTSD is so persistent and why the most effective treatments work by directly modifying trauma memory encoding, not by managing symptoms.

The Four Symptom Clusters

For a PTSD diagnosis, all four of the following symptom clusters must be present for at least one month and cause significant functional impairment.

Re-Experiencing

Flashbacks, reliving the traumatic event including physical symptoms such as a racing heart or sweating; intrusive memories; nightmares; and intense distress when reminded of the trauma. Re-experiencing symptoms involve the involuntary intrusion of trauma-related content into current experience.

Avoidance

Deliberately avoiding trauma-related thoughts, feelings, memories, people, places, or activities. Avoidance reduces short-term distress but maintains and often worsens PTSD over time by preventing the brain from processing and integrating the traumatic memory.

Negative Cognition and Mood

Staying away from places, events, or objects that are reminders of the experience; distorted blame of self or others; persistent negative beliefs about oneself or the world; emotional numbing; detachment from others; and loss of interest in activities. This cluster often overlaps with depression and can make PTSD difficult to distinguish from major depressive disorder without a complete evaluation.

Hyperarousal

Hypervigilance, exaggerated startle response, irritability or angry outbursts, difficulty concentrating, and sleep disturbance. Hyperarousal reflects a chronically activated threat-detection system. The nervous system remains on high alert because the brain has not updated its assessment of threat level.

These four core symptom areas must last longer than one month and be severe enough to interfere with daily life, such as relationships or work. Onset is usually within three months of the traumatic event but can emerge years later in some presentations.

Who Develops PTSD

Not everyone who experiences trauma develops PTSD. Aspects of the traumatic event and certain biological and social factors may make some people more likely to develop PTSD. Previous exposure to adversity and other traumatic experiences, especially in childhood, can increase a person’s chance of developing PTSD later in life.

Factors associated with higher PTSD risk include: prior trauma history, female sex, lower social support following the trauma, greater severity or duration of the traumatic event, and having a close relative with a history of anxiety or PTSD. Genetic factors contribute, though no single gene determines outcome.

People with PTSD often have co-occurring conditions such as depression, substance use, or anxiety disorders. The presence of comorbid conditions is not uncommon, and addressing them as part of the treatment plan produces better outcomes than treating PTSD in isolation.

The 2025 APA Clinical Practice Guideline: What It Recommends

The APA’s latest Clinical Practice Guideline for the Treatment of PTSD in Adults, approved in 2025, is an update to the 2017 guideline and now draws from 15 systematic reviews of interventions. The updated guideline places greater emphasis on complex presentations, outcomes beyond symptom reduction (quality of life, functioning), and barriers to treatment access.

Trauma-Focused Psychotherapy: The Gold Standard

The APA strongly recommends four trauma-focused psychotherapies as first-line treatment: Cognitive Processing Therapy (CPT), Prolonged Exposure (PE), EMDR, and Cognitive Therapy. A network meta-analysis of 98 randomized controlled trials found that CPT, EMDR, cognitive therapy, narrative exposure therapy, PE, and CBT were all significant in reducing PTSD symptoms, with EMDR and CPT showing large effect sizes in both short-term and long-term follow-up.

Cognitive Processing Therapy (CPT) addresses the distorted thoughts and beliefs about the trauma, the self, and the world that maintain PTSD. It typically takes 12 sessions.

Prolonged Exposure (PE) works through gradual, structured engagement with trauma-related memories and avoided situations. By confronting rather than avoiding the trauma in a safe therapeutic context, the fear response diminishes through a process called inhibitory learning.

EMDR (Eye Movement Desensitization and Reprocessing) involves bilateral stimulation (typically eye movements) while processing trauma memories. The mechanism is not fully understood, but the evidence is robust: EMDR is one of the most studied trauma therapies and is recommended in major guidelines including the VA/DoD and APA.

All three of these therapies share a common thread: they work directly with the trauma memory, not around it. This is why avoidance-based coping and benzodiazepines, which help patients avoid distress, actually interfere with these treatments.

Medications: SSRIs and the PTSD-Specific Evidence

The FDA has approved sertraline (Zoloft) and paroxetine (Paxil) as the only medications specifically for PTSD. Both are SSRIs. They address comorbid depression and anxiety, and can reduce hyperarousal and intrusive symptoms.

Current treatment guidelines recommend that if SSRIs are used, they should not be the sole treatment, as psychotherapy targeting the trauma is the most evidence-supported intervention. Medication and trauma-focused therapy used together typically produce better outcomes than either alone for moderate to severe PTSD with comorbid conditions.

Prazosin, an alpha-1 blocker, has evidence for reducing trauma-related nightmares specifically and is listed in VA/DoD guidelines as a suggested option for that symptom.

Why Benzodiazepines Are Not Recommended

This point is worth emphasizing because benzodiazepines are commonly prescribed for anxiety and are sometimes given to patients presenting with PTSD-related distress.

Current VA/DoD and APA guidelines recommend against benzodiazepines for the treatment of PTSD. They may provide short-term relief for acute anxiety but are associated with increased intrusive and dissociative symptoms over time and can interfere with the fear extinction process required for trauma-focused therapy.

Trauma-focused therapies work by allowing the fear response to activate and then diminish without avoidance. Benzodiazepines, by suppressing the fear response, prevent this process from occurring and can actually undermine the therapy’s effectiveness. They are not a bridge to treatment for PTSD. They are contraindicated with the most effective treatments.

“Benzodiazepines are sometimes the medication people expect to receive for PTSD because they know anxiety is part of it,” says Elizabeth Lokenauth, PA-C, of the SiggyMD clinical team. “The evidence is clear that they make the condition worse over time for most people with PTSD. The combination of SSRIs for the depression and anxiety component, and trauma-focused therapy for the underlying trauma processing, is what the guidelines support.”

The Treatment Gap in PTSD Care

Despite strong evidence for effective treatments, most people with PTSD do not receive guideline-concordant care. There has been no new FDA approval for a PTSD treatment in more than 15 years, and no drug currently treats all four core symptom areas effectively.

Clinician training is also a barrier: CPT and EMDR require specific training, and many mental health providers are not trained in either. Patients may see several providers before receiving trauma-focused therapy.

People with PTSD often have co-occurring conditions such as depression, substance use, or anxiety disorders. Addressing those comorbidities as part of a comprehensive plan, rather than treating only the PTSD or only the depression, improves overall outcomes.

About SiggyMD

SiggyMD provides clinician-reviewed care for depression and anxiety, including the depression and anxiety that frequently co-occur with PTSD. The anonymous intake gathers the full clinical picture, including trauma history. A licensed prescriber reviews every case before any treatment plan is approved.

For people managing PTSD alongside depression or anxiety, Siggy’s daily check-ins track mood, symptoms, and medication response continuously, not just at quarterly appointments.

If you are struggling with symptoms of PTSD, depression, or anxiety and want to start a clinical conversation, start your anonymous intake with SiggyMD. No name, no email, no account required.

For a related perspective on navigating PTSD day-to-day, read our post on managing PTSD between appointments. For more on the clinical overlap between PTSD and complex trauma, see our post on complex PTSD vs. PTSD.

What Members Are Saying

TL

T.L., 43

PTSD

“I had been prescribed a benzodiazepine for anxiety related to my PTSD for two years before a new prescriber explained that the medication was likely making my intrusive symptoms worse. Switching to an SSRI and starting CPT was the first time I felt actual progress. The benzodiazepine had been managing my distress in the moment but keeping me stuck.”

AM

A.M., 36

PTSD with Comorbid Depression

“I had PTSD and depression simultaneously and felt like no one could figure out which to treat first. What helped was a prescriber who was willing to treat both at the same time: medication for the depression and anxiety, and a referral to a therapist trained in PE for the PTSD. It took six months, but it was the most progress I had made in years.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

The Bottom Line

PTSD is a biologically grounded condition with strong evidence-based treatments. The most effective are trauma-focused psychotherapies, CPT, PE, and EMDR, that work by directly modifying how the brain processes the traumatic memory.

Medications play a supporting role, particularly for comorbid depression and anxiety. Benzodiazepines are explicitly not recommended and can interfere with the most effective treatments.

The treatment gap in PTSD care is real: many people see multiple providers before receiving guideline-concordant care. Knowing what the evidence recommends, and asking specifically for it, is a meaningful step toward getting treatment that works.

Sources

1. National Institute of Mental Health. Post-Traumatic Stress Disorder (PTSD). NIMH. Accessed June 2026.

2. National Institute of Mental Health. Post-Traumatic Stress Disorder Brochure. NIMH. Accessed June 2026.

3. American Psychological Association. Clinical Practice Guideline for the Treatment of PTSD in Adults. APA. 2025.

4. Yunitri N, et al. Comparative effectiveness of psychotherapies in adults with PTSD: a network meta-analysis of randomised controlled trials. Psychological Medicine. 2023;53(13):6376-6388. (DOI: 10.1017/S0033291722003737)

5. Schrader C, Ross A. A Review of PTSD and Current Treatment Strategies. Missouri Medicine. 2021;118(6):546-551.

6. VA/DoD. The Management of Posttraumatic Stress Disorder and Acute Stress. Annals of Internal Medicine. 2024.

7. Policy Center for Mental Health. Post-Traumatic Stress Disorder: One Pager. 2024.

8. Medscape. Posttraumatic Stress Disorder Guidelines. Accessed June 2026.

9. APA Monitor. PTSD and Trauma: New APA Guidelines Highlight Evidence-Based Treatments. 2025.